Drug profile · INN
faricimab-svoa
VABYSMO
faricimab-svoa (VABYSMO) is a angiopoietin-2 inhibitor. Route of administration: intravitreal. Current US regulatory status: approved.
Drug details — faricimab-svoa
- US status
- approved
- Class
- —
- Route
- INTRAVITREAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
faricimab-svoa (VABYSMO) is a angiopoietin-2 inhibitor. Route of administration: intravitreal. Current US regulatory status: approved.
Key facts
Mechanism of action
Angiopoietin-2 inhibitor
Primary target: Angiopoietin-2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Related & competitor drugs
Frequently asked questions
What is faricimab-svoa?
faricimab-svoa (VABYSMO) is a angiopoietin-2 inhibitor. Route of administration: intravitreal. Current US regulatory status: approved.
What is the brand name for faricimab-svoa?
VABYSMO is a marketed brand name for faricimab-svoa. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of faricimab-svoa?
faricimab-svoa has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.